March 5, 2024
“…Adria Cimino (Intellia Therapeutics): Intellia stock has dropped more than 80% below its high over the past three years, even as this CRISPR gene-editing specialist moves closer to the finish line with its lead candidates. And this could offer bargain-hunting investors looking for… Continue Reading…
Recent Comments